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12 Associated conditions in cystic ﬁbrosis: ﬁndings at diagnosis and
changes in time, impact on clinical outcomes and quality of life
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University, Respiratory Diseases, Brasov, Romania; 2Victor Babes University,
County Hospital Timisoara, Genetics, Timisoara, Romania
Objectives: To determine the burden of associated conditions in Cystic Fibrosis
and their impact on clinical outcomes in a pediatric cohort.
Methods: Retrospective clinical ﬁle analysis of pediatric CF patients followed up
during 1999–2013, correlated with diagnosis of CF and non CF related associated
conditions.
Results: 56 patients followed up, mean age at diagnosis 11 months, 22/56 died
(11 before the age of 1 year). Causes of early deaths: severe lung disease and
malnutrition correlated with poor socioeconomic status. 13/56 had meconium ileus
(2/56 meconium peritonitis, 2/56 parcelar intestinal athresia), all underwent surgery
with difﬁcult recovery and high rate of complications. Related CF conditions:
4/56 nasal polyposis, 4/56 CFrelated diabetes, 5/56 early CFRLD, 4/56 ABPA;
all negatively impacted clinical outcomes. Diagnosis of other chronic diseases in
13/56 patients (some genetic traits): juvenile myoclonic epilepsia (1/56), horseshoe
kidney (1/56), spastic paraparesis (1/56), congenital cardiac malformations (4/56),
ADHD (3/56), asthma and allergic rinitis (4/56). Higher rate of hospitalization,
lower clinical and radiological scores were observed in patients with CF related
conditions (p< 0.05). Quality of life was negatively impacted by both presence of
CF related and nonCF related conditions, regardless age.
Conclusion: Associated CF related conditions are frequent observed as survival
increases in CF. Diagnosis of other chronic conditions in CF may negatively impact
clinical outcomes, more so with increasing of age. Early diagnosis of other chronic
traits in CF, specialized and multidisciplinary care is needed to improve QoL and
life span.
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Objectives: Newborn screening (NBS) in cystic ﬁbrosis (CF) enables earlier
treatment and improve prognosis of children with CF.
Methods: A two-step IRT/IRT protocol was employed for CF screening in 2007 in
Russian Federation. Infants with a raised second IRT measurement (IRT-2 greater
than 40mg/L) at day 21−28 are referred for sweat testing at the local Neonatal
Screening Laboratory or Regional CF Centre. Infants with a normal sweat test are
monitored by their local doctor for one year. Infants with an equivocal sweat test
result are offered DNA analysis for common CF causing mutations, but funding is
currently an issue and families must pay for this investigation themselves. Infants
with a positive sweat test are referred to one of 57 regional CF Centres.
Results: Data from 2007 to 2012 show an incidence of CF in Russia as 1:10,000
(median 1:9,854) with signiﬁcant difference in geographical regions, from 1:7,000
in Central, South and Far East regions to 1:17,000 in North-West. This incidence
of CF is likely to be an underestimate as up to 20% of infants with positive IRT-2
do not come for the sweat test in some regions.
Conclusion: The National CF NBS programme has resulted in earlier detection
of infants with CF and a clearer picture of the incidence of this condition in our
population. The NBS programme has driven an improvement in the provision and
models of CF care models across Russia. The main problems have a lack of central
funding for DNA analysis, lack of CF centres and specialists in some regions and
absence of a National CF Registry.
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Objectives: Newborn screening (NBS) in cystic ﬁbrosis (CF) enables earlier treatment
of infection and monitoring nutritional state, both of which improve prognosis. ECFS
Neonatal Screening Working Group (NSWG) was established to track current practices
in NBS, support implementation of NBS and establish consensus on issues arising in
NBS. NSWG last conducted a survey on NBS in Europe in 2004/05. We aim to provide
1) an update on NBS, 2) discuss differences between protocols and 3) identify barriers
to establishing NBS programmes.
Methods: Three questionnaires were sent to physicians worldwide in 2012/13, each
speciﬁc to countries without NBS, national NBS programmes and regional NBS
programmes.
Results:
1. 75 replied, an increase from 26 replies in 2004/05; 17 without a programme, 16 with
national programmes and 42 with regional programmes from 10 countries.
2. 9 national and 23 regional programmes use IRT/DNA, 4 national and 13 regional
use IRT/IRT, 2 national and 4 regional use IRT/PAP and 1 national uses IRT/High
Resolution Melt. 2 regional responses did not specify a protocol. IRT/DNA had a
higher positive predictive value (mean 37%, range 5–100%) at the cost of more
equivocal diagnosis and recognising more carriers compared to IRT/IRT (mean 6%,
range 3−10%). Mean sensitivity in both protocols is 97% with similar ranges. There
was variability in IRT cut-off, age at testing and second tier strategies.
3. Lack of ﬁnancial support was the chief barrier to implementation of NBS, reported
by 10 of 17, however 4 reported they expect to start a programme soon.
Conclusion: NBS is rapidly gaining support. Differences observed indicate a need to
establish an optimal protocol.
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Background: In 2011, Switzerland started newborn screening (NBS) for cystic ﬁbrosis
(CF). We investigated the parents’ satisfaction with the screening, in particular:
1. their opinion on the information given about the screening;
2. their feelings during the screening process; and
3. their overall approval of the screening.
Methods: All positively screened children were invited by phone call from the nearest
CF centre for further investigations including sweat tests. After the visit, parents
were given an anonymous questionnaire to assess different aspects of the screening
procedure.
Results: By December 2013, 256 children had a suspicious screening result and were
referred to a CF centre. The questionnaire was distributed to 249 families and returned
by 123 (49%). The information from the maternity ward was rated as satisfactory by
62% of families (n = 74), the additional information received in the CF centre for 91%
(n = 112). After the phone call from the CF centre, most parents (92; 79% of 117
contacted by phone) felt troubled or anxious. After the visit, only 45 families (37%)
remained anxious: 15/79 families with a healthy child (19%) and 29/44 families with
a child who had CF (66%; p< 0.001). Most parents (110; 90%) were glad that their
child had been screened, only 3 (2%) were unhappy about it and 10 not sure (8%) −
independent of the ﬁnal CF diagnosis (p = 0.345).
Conclusion: The personal information in the CF center is important for anxious parents
and helps them to compose themselves. The large majority of families, independent of
the ﬁnal CF diagnosis, was grateful that the screening had been performed.
